A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the Cisterna Magna of Adult Subjects With Frontotemporal Dementia and Mutations in the Progranulin Gene A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Ph ...
Frontotemporal Dementia
Drug: PBFT02
Passage Bio, Inc.
NULL
Recruiting
35 Years
75 Years
All
15
Phase 1/Phase 2
United States;Brazil;Canada;Italy;Portugal;United Kingdom